[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-operative-atrial-fibrillation-after-coronary-artery-bypass-grafting-cabg\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-operative-atrial-fibrillation-after-coronary-artery-bypass-grafting-cabg":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100637774","phase-2-colchicine-for-the-prevention-of-post-operative-atrial-fibrillation-after-coronary-artery-bypass-grafting-a-single-center-strategy-stratified-randomized-double-blind-placebo-controlled-trial-100637774",false,"NCT07611019","Colchicine for the Prevention of Post-Operative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Single-Center, Strategy-Stratified, Randomized, Double-Blind, Placebo-Controlled Trial","Randomized, Double-Blind, Placebo-Controlled Trial of Colchicine to Prevent Post-Operative Atrial Fibrillation After CABG With Strategy-Stratified Randomization","Inclusion Criteria:\n\n* Adults aged 20 years or older scheduled to undergo elective coronary artery bypass grafting (CABG), including either off-pump CABG or on-pump CABG.\n* Ability to receive oral study medication before and after surgery.\n* Provision of written informed consent before randomization.\n\nExclusion Criteria:\n\n* History of atrial fibrillation or atrial flutter before surgery.\n* Severe renal impairment (estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m²) or chronic dialysis.\n* Severe hepatic dysfunction.\n* Known hypersensitivity or previous severe adverse reaction to colchicine.\n* Pregnancy or breastfeeding.\n* Current use of strong CYP3A4 or P-glycoprotein inhibitors that cannot be safely discontinued or substituted.\n* Any condition judged by the investigators to interfere with study participation or safety assessment.","ALL","20 Years",{"count":19,"type":20},400,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","Post-operative atrial fibrillation after coronary artery bypass grafting (CABG)",[27],"Post-Operative Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG)",[29,30,31,32,33,34,35,36],"colchicine","postoperative atrial fibrillation","coronary artery bypass grafting","off-pump surgery","cardiopulmonary bypass","pharmacokinetics","inflammation","neutrophil extracellular traps","NOT_YET_RECRUITING","2026-05-20",{"date":40,"type":41},"2026-05-28","ACTUAL",{"date":43,"type":20},"2026-06",{"date":45,"type":20},"2028-07",{"name":47,"class":48},"National Taiwan University Hospital","OTHER"]